Accelerated Approval Study Triple Negative Breast Cancer

http://www.marketwatch.com/story/celldex-therapeutics-initiates-metric-an-accelerated-approval-study-of-glembatumumab-vedotin-in-patients-with-triple-negative-breast-cancer-2013-12-02?reflink=MW_news_stmp

Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer

Antibody drug conjugate targets gpNMB, a protein which promotes the migration, invasion and metastasis of breast cancer


 

Categories